信迪利单抗治疗晚期非小细胞肺癌的临床观察  

Clinical Observation of Sintilimab in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：齐甜甜 史婉婷 陈剑[2] 

机构地区：[1]青岛大学,山东 青岛 [2]青岛大学附属烟台毓璜顶医院肿瘤科,山东 烟台

出　　处：《临床医学进展》2021年第12期5625-5630,共6页Advances in Clinical Medicine

摘　　要：目的:探讨信迪利单抗注射液单药疗法治疗晚期非小细胞肺癌的有效性和安全性。方法:选取2020年9月至2021年10月烟台毓璜顶医院收治的20例化疗失败或无法耐受化疗的晚期非小细胞肺癌患者,使用信迪利单抗注射液单药免疫治疗,评估患者的客观缓解率(overall response rate, ORR)、疾病控制率(disease control rate, DCR)、无进展生存期(progression free survival, PFS)、总生存期(overall survival, OS)和不良反应发生情况。结果:随访2~13个月,中位随访时间为6.5个月。所有患者的ORR为40.0% (8/20),DCR为80.0% (16/20);治疗相关不良反应发生率为60.0% (12/20),不良反应以1~2级为主,≥3级不良反应发生率为15.0% (3/20)。结论:对于化疗失败或无法耐受化疗的晚期非小细胞肺癌患者,信迪利单抗注射液单药疗法不失为一种较好的治疗选择,安全性较好,并能降低血清CEA、LDH水平,改善患者生活质量。OBJECTIVE: To explore the efficacy and safety of sintilimab injection in the treatment of advanced non-small cell lung cancer. METHODS: Patients with advanced non-small cell lung cancer who failed chemotherapy or could not tolerate chemotherapy in Yantai Yuhuangding Hospital from September 2020 to October 2021 were extracted and treated with sintilimab injection immunotherapy. The overall response rate (ORR), disease control rate (DCR), progression free survival (PFS), overall survival (OS) and incidence of adverse drug reactions were evaluated. RESULTS: The follow-up period was from 2 to 13 months, and the median follow-up time was 6.5 months. The ORR of all patients was 40.0% (8/20), the DCR was 80.0% (16/20), and the incidence of treatment- related adverse drug reactions was 60.0% (12/20). Adverse drug reactions were mainly in level 1 to 2, and level ≥ 3 was 15. 0% (3/20). CONCLUSIONS: For patients with advanced non-small cell lung cancer who have failed chemotherapy or cannot tolerate chemotherapy, monotherapy with sintilimab is a better treatment option with higher safety, and can reduce the levels of serum CEA and LDH and improve the quality of life of patients.

关 键 词：信迪利单抗 PD-1 PD-L1 免疫疗法 不良反应 非小细胞肺癌 

分 类 号：R73[医药卫生—肿瘤]